|[April 21, 2014]
Shiseido Opens Research Facility Dedicated to Hair Regeneration
TOKYO --(Business Wire)--
Co., Ltd. (TOKYO:4911) announces plans to open the Shiseido
Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center,
located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan,
will centralize research and development on hair regenerative medicine
with an aim toward commercialization.
Research at Shiseido Cell-Processing and Expansion Center (Photo: Business Wire)
Regenerative medicine in Japan is an emerging industry which the
government aims to foster through new legislation and revisions to
existing law as part of economic reform strategies, in order to advance
in this field. Shiseido has a long history of conducting comprehensive
research and working towards commercialization of the regenerative
medicine for hair.
Shiseido's hair regenerative medicine technology
With the goal of clinical application of regenerative medicine to treat
alopecia and thinning hair, Shiseido concluded a technical collaboration
agreement in July 2013 with a Canadian bio-venture company RepliCel
Life Sciences Inc. (hereinafter referred to as "RepliCel") acquiring
an exclusive geographic license to use RepliCel Hair-01 (RCH-01) hair
regeneration technology in Asia, including Japan.
RCH-01 has been developed over 10 years of scientific research, and safe
application in humans has been validated by RepliCel's phase 1 clinical
trial. RepliCel has patents issued for hair follicle mesenchymal stem
cells and their usage in Japan, the United States, Australia and the EU.
RCH-01 is an "autologous cell transplantation technology," in which
specific cells(1) isolated from the hair follicles(2) taken
from the scalp of a patient are cultured and implanted (injected) into
the balding scalp area, potentially stimulating residing hair follicles
and promoting new growth in the balding scalp area.
Sheath Cup cells, which are believed to play an important role in
promoting hair growth
(2) A hair follicle is a skin organ composed
of various cell types that support hair growth and structure.
Kobe Biomedical Innovation Cluster
The Kobe Biomedical Innovation Cluster is one of the core bases of the
Kansai Innovation International Strategic Comprehensive Special Zone
designated by the Japanese government to promote industrial development
in advanced medicine and to provide a competitive advantage in the
international market. It is the largest national cluster zone
specialized in life sciences, with the focus on promoting translation of
leading scientific research and advanced knowledge in regenerative
medicine into clinical use.
Kobe Biomedical Innovation Cluster
in Kobe Port Island, it has been endorsed by the city of Kobe to
promote its commercialization through integration of industry,
academia, and government. There are over 270 biomedical companies,
academic, medical, and government organizations situated in this area
and working in collaboration towards clinical application of
regenerative medicine, and the development of new pharmaceutical
products and medical equipment.
Business Support Center for Biomedical Research
SPEC will be located in the Business Support
Center for Biomedical Research Activities, a core facility consisting
of research and CPC (News - Alert) sections. It has been built to provide support and
space for research and commercialization of regenerative medicine.
1-5-5 Minatojimaminamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047, Japan
For more information, please visit: http://www.shiseido.co.jp/releimg/2289-e.pdf
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140421005994/en/
[ Back To TMCnet.com's Homepage ]